A longitudinal follow-up cohort based on metabolomics and testing big data for the study of biomarkers for diagnosis, progression, and prognosis of retinal neovascular diseases

Status

Recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2000032439

Enrollment

Unknown

Registered

2020-04-28

Start date

2020-09-01

Completion date

Unknown

Last updated

2020-05-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Age-related macular degeneration

Interventions

Gold Standard:Glaucomatous optic neuropathy such as a vertical cup disk ratio (VCDR) > 0.7 or an inter-eye asymmetry of > 0.2, with notching, rim thinning, or retina nerve fiber layer (RNFL) defect

Visual field defect that corresponds to the structural change.

Index test:Intraocular&#32

pressure?visual&#32

field?optic&#32

nerve&#32

structural&#32

tests Metabonomics

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Case Group: Patients with severe phenotype of AMD and Dr should be selected preferentially; 2. Control Group: Patients without any sign of AMD or Dr.

Exclusion criteria

Exclusion criteria: 1. Patients with other diseases that seriously damage vision and visual field, including retinitis pigmentosa, glaucoma, pathological myopia, neovascular glaucoma, uveitis, blunt ocular trauma, etc; 2. Patients with immune system diseases; 3. Patients with other hereditary eye diseases and hereditary diseases.

Design outcomes

Primary

Measure	Time frame
metabolomics;Sensitivity, specificity, positive predictive value, negative predictive value;	—

Countries

China

Contacts

Public ContactCao Wenjun

Fudan University Affiliated ophthalmotolaryngology hospital

wgkjyk@aliyun.com+86 18917785088

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026